Lutetium-177 Supply Market Global Report 2026

The lutetium-177 supply market size has grown rapidly in recent years. It will grow from $1.4 billion in 2025 to $1.63 billion in 2026 at a compound annual growth rate (CAGR) of 15.7%. The growth in the historic period can be attributed to rising prevalence of cancer indications requiring targeted radionuclide therapy, increasing clinical adoption of radiopharmaceutical treatments, expansion of nuclear medicine infrastructure globally, growing investments in medical isotope production facilities, increasing regulatory approvals for lutetium-177 based therapies.

The lutetium-177 supply market size is expected to see rapid growth in the next few years. It will grow to $2.94 billion in 2030 at a compound annual growth rate (CAGR) of 15.9%. The growth in the forecast period can be attributed to growing demand for precision oncology treatments, increasing expansion of commercial radiopharmaceutical manufacturing capacity, rising investments in advanced isotope production technologies, increasing development of novel lutetium-177 therapeutic applications, growing establishment of regional isotope supply networks. Major trends in the forecast period include increasing expansion of reactor based isotope production capacity, growing focus on high purity lutetium-177 supply chains, rising investments in radiopharmaceutical logistics infrastructure, increasing adoption of non carrier added lutetium-177 production methods, growing emphasis on regulatory compliant isotope transportation networks.

The rising prevalence of cancer is expected to propel the growth of the lutetium-177 supply market going forward. Cancer is a group of diseases characterized by the uncontrolled growth of abnormal cells that can invade surrounding tissues and spread to other parts of the body. The prevalence of cancer is increasing due to the aging population, as older age remains one of the most significant risk factors for the development of most cancer types, with a large proportion of cases occurring in individuals aged 65 years and above. Lutetium-177 supply supports targeted cancer therapies by delivering precise radiation directly to tumor cells while minimizing damage to healthy tissues, improving treatment outcomes for neuroendocrine tumors and metastatic prostate cancer and advancing personalized oncology care globally. For instance, in February 2024, according to the World Health Organization, a Switzerland-based international organization, more than 35 million new cancer cases are projected by 2050, representing a 77% increase from the estimated 20 million cases reported in 2022. Therefore, the rising prevalence of cancer is driving the growth of the lutetium-177 supply market.

Major companies operating in the lutetium-177 supply market are focusing on developing advanced initiatives, such as large-scale commercial radioisotope production platforms, to improve the availability, reliability, and scalability of medical isotopes used in targeted cancer therapies and diagnostic imaging applications. Large-scale commercial radioisotope production platforms are sophisticated manufacturing systems designed to generate medical isotopes in high volumes through scalable irradiation and purification processes, ensuring a stable, dependable, and continuous supply of therapeutic and diagnostic isotopes for cancer treatment and nuclear medicine applications. For instance, in January 2025, Nusano Inc., a US-based radioisotope development company, launched commercial isotope operations and announced a lutetium-177 supply agreement with GlyTherix. This initiative supports the production and distribution of Lu-177 for targeted radiopharmaceutical therapies while also providing future access to isotopes such as actinium-225, zirconium-89, lead-212, and terbium-161. Nusano’s flagship facility in West Valley City, Utah, is designed to simultaneously produce up to 12 different radioisotopes and ultimately support a portfolio of more than 25 isotopes for life sciences applications. The platform strengthens isotope supply reliability for clinical trials and commercial therapeutic programs, particularly for oncology-focused radiopharmaceuticals that target aggressive cancers through precision molecular therapies.

In July 2023, ITM Isotope Technologies Munich SE, a Germany-based radiopharmaceutical biotechnology company specializing in the manufacturing of non-carrier-added Lutetium-177, partnered with POINT Biopharma Global Inc. to expand their global supply agreement for non-carrier-added Lutetium-177 (n.c.a. ^177Lu). Through this partnership, ITM Isotope Technologies Munich SE and POINT Biopharma Global Inc. aim to support the clinical and potential future commercial development of ^177Lu-based radiopharmaceuticals across POINT’s oncology pipeline by ensuring a scalable and dependable supply of high-purity medical radioisotopes. POINT Biopharma Global Inc. is a US-based radiopharmaceutical company engaged in the discovery, development, and commercialization of targeted radioligand therapies for cancer treatment.

Major companies operating in the lutetium-177 supply market are Novartis AG; Telix Pharmaceuticals Limited; Bayer AG; Cardinal Health Inc.; Siemens Healthineers AG; Curium International Trading B.V.; Eckert & Ziegler SE; NRG PALLAS B.V.; State Atomic Energy Corporation Rosatom; Framatome SAS; BWX Technologies Inc.; National Centre for Nuclear Research Radioisotope Centre POLATOM; Isotopia Molecular Imaging Ltd.; Nusano Inc.; ITM Isotope Technologies Munich SE.

North America was the largest region in the lutetium-177 supply market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lutetium-177 supply market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the lutetium-177 supply market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The lutetium-177 supply market consists of sales of radiopharmaceutical isotopes, radioactive source materials, isotope processing equipment, shielding containers, and related nuclear medicine products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The lutetium-177 supply market research report is one of a series of new reports that provides lutetium-177 supply market statistics, including lutetium-177 supply industry global market size, regional shares, competitors with a lutetium-177 supply market share, detailed lutetium-177 supply market segments, market trends and opportunities, and any further data you may need to thrive in the lutetium-177 supply industry. This lutetium-177 supply market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.